저자들은 1987년 3월부터 1988년 2월까지 1년간 서울대학교병원 산부인과에 입원한 부인과 악성종양 환자 17명을 대상으로 HTSCA, in vitro clonogenic assay를 시행하여 인터페론 및 화학요법제에 대한 감수성 검사를 시행하여 다음과 같은 결론은 얻었다. 1. 환자의 평균 연령은 50세였고, 전체 대상환자 17례중 자궁경암이 11례, 난소암이 6예였다. 2. 자구경암은 11례중 4례(36.4%)난소암은 6예중 4예(66.7%)에서 성장을 보였으며, 전체환자 17례중 8예에서 성장을 보여 47.1%의 성장율 성적을 보였다. 3. 인터페론에 대한 부인과 악성종양세포의 감수성을 보면 인터페론 1000unit/ml에서는 8예 중 4례(50%)에서 감수성을 보였으며 3000unit/ml에서는 8예중 5례(62.5%)에서 감수성을 보였 다. 4. 난소암에서 화학요법제의 최대혈장농도의 1/10과 최대혈장농도에서의 감수성은 각각 epirubicin에서는 75% 및 75%, cis-platin에서는 100% 및 100%, cytoxan에서는 50% 및 75%이 었다. 5. 자궁암에서 화학요법제의 최대혈장농도의 1/10과 최대혈장농도에서의 감수성은 각각 epirubicin은 75% 및 75%, cis-platin에서는 75% 및 75% 5-FU에서는 75% 및 75%이었다. 6. 인터페론에 감수성을 보이는 경우 적어도 한가지 이상의 화학요법제에 감수성을 보이는 것으로 나타났다.

In vitro clonogenic assay provides a way of testing the effectiveness of chemotherapeutic agents in treatment of cancer as well as a study of tumor biology. There has been considerable recent interest in the antiproferative and antitumor effects of interferon on the part of both basic scientists and clinicians. Tumor spectimens from 17 patients having cervicla or ovarian carcinomas were studies with the in vitro clonogenic assay for testing of sensitivity to interferon and various chemotheprapeutic agents from May, 1987 to February, 1988 at the Department of Obsterics and Gyunecology Seoul National Unviersity Hospital. The results were as follows; 1. The mean age of patients was 50 years and among the total of 17 patients , 11 cases were cervical carcinoma and 6 were ovarian carcinomas. 2. The percentage of tumor specimen which grew in the soft agarose plate was 47.1%. Of the 11 cervical cancer studied , 4 grew (36.4% growth rate). Of the 6 ovarian cancer tested in the laboratory, 4 grew (66.7%). 3. Response to interferon was 50% in the concetration of 1000 units/ml and 62.5% in the concentration of 3000 unit/ml. 4. In ovarian cancer specimens response to Epirubicin was 75% at 1/10 peak plasma level and 75% at peak plasma level. Response to Cis-platin were 100% and 100% at each plasma level. Responses to cytoxan were 50% nad 75%. 5. In cervical cancer specimens, response to Epirubicin was 75% at 1/10 peak plasmal level and 75% at peak plasma level, Responses to Cis-platin were 75% and 75% at each plasma level. Responses to 5-FU were 75% and 75%. 6. Tumors that were sensitive to interferon were also sensitive to at least one other chemotherpeutic agents.